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Introduction: Not all breast cancer patients respond to tamoxifen treatment, possibly due to genetic
predisposition. As tamoxifen-induced reductions in percent mammographic density (PMD) have been linked to the
risk and prognosis of breast cancer, we conducted a candidate gene study to investigate the association between
germline CYP2D6 polymorphisms and PMD change.
Methods: Baseline and follow-up mammograms were retrieved for 278 tamoxifen-treated subjects with CYP2D6
metabolizer status (extensive (EM), heterozygous extensive/intermediate (hetEM/IM) or poor metabolizer (PM)).
Logistic regression analyses were conducted comparing subjects who experienced >10% reduction in PMD to
those who experienced ≤10% reduction or increase.
Results: After multivariate adjustment, PMD change was found to be significantly associated with the degree of
CYP2D6 enzyme functionality (Ptrend = 0.021). Compared with EM, hetEM/IM and PM were 72% (95% confidence
interval (CI): 0.10 to 0.79) and 71% (0.03 to 2.62) less likely to experience a >10% reduction, respectively.
Conclusions: Tamoxifen-induced change in PMD appears to have a genetic component.Introduction
Tamoxifen reduces both the risk and recurrence of
breast cancer [1,2]. It has recently been shown that a de-
crease in mammographic density predicts response to
tamoxifen [3-5]. There may be genetic reasons as to why
some women experience a decrease in mammographic
density and a dramatic influence on risk and prognosis
of breast cancer. While tamoxifen metabolism is complex,
it is known that the Cytochrome P450 2D6 (CYP2D6)
enzyme is necessary to produce clinically active metabo-
lites - 4-hydroxytamoxifen and endoxifen. It has been sug-
gested that patients with no functional CYP2D6 alleles
should be offered alternatives to tamoxifen [6,7]. We thus
hypothesize that only women who are able to metabolize
tamoxifen would experience a decrease in density and a
potential parallel effect on breast cancer risk and prog-
nosis. In this study, we explored the association between* Correspondence: per.hall@ki.se
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reproduction in any medium, provided the orCYP2D6 metabolizer phenotype and mammographic dens-
ity change, using breast cancer cases from a population-
based breast cancer case–control study conducted in
Sweden between 1993 and 1995 [8-10].
Methods
Study population
Subjects were a subset of the CAncer Hormone Replace-
ment Epidemiology in Sweden (CAHRES) study [8].
Briefly, the parent study consisted of women born in
Sweden who were 50 to 74 years old at first diagnosis of
invasive breast cancer in the Swedish Cancer Register.
Approval for the study was given by the ethical review
boards in the respective regions in which the sub-
jects were based: Gothenburg, Linköping, Lund, Umeå,
Uppsala and at the Karolinska Institute in Stockholm. Sub-
jects are protected by the informed consent process, in
which they were told what was collected and repeatedly
given the option of declining to participate. All subjects
were informed in writing about the study and that partici-
pation was voluntary. The participants have all given theirhis is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.








n = 247 n = 31
Baseline characteristics
Age (years) 63.8 ± 6.2 61.5 ± 5.9 0.05
BMI (kg/m2) 25.4 ± 3.7 24.1 ± 4 0.02
HRT ever 0.10
No 106 (42.9) 8 (25.8)
Yes 141 (57.1) 23 (74.2)
Baseline PMD 14.7 ± 9.5 32 ± 9.1 <0.001
Time between
mammograms (years)
1.9 ± 0.6 2.0 ± 0.5 0.30
Tumor characteristics
ER status 0.15
Positive 167 (67.6) 26 (83.9)
Negative 29 (11.7) 1 (3.2)
Missing 51 (20.6) 4 (12.9)
Treatment
Chemotherapy 0.48
No 236 (95.5) 31 (100)
Yes 11 (4.5) 0 (0)
Li et al. Breast Cancer Research 2013, 15:R93 Page 2 of 7
http://breast-cancer-research.com/content/15/5/R93consent in using their DNA for genetic analyses. The
process of selection of breast cancer cases included in the
current study is summarized in Table 1.
DNA source and genotyping
As described previously in [11], DNA was isolated from
3 ml of whole blood with the Wizard Genomic DNA
Purification Kit (Promega, Madison, WI, USA) in ac-
cordance with the manufacturer's instructions; while
DNA from non-malignant cells in paraffin-embedded
tissue was extracted by using a standard phenol/chloro-
form protocol [11,12]. Our initial study set in this bio-
marker study consisted of 710 tamoxifen-treated breast
cancer cases genotyped for CYP2D6. DNA from tumor
tissue or blood was assayed for polymorphisms associ-
ated with reduced (*10, *41) or absent (*3, *4, *5) enzyme
activity, as described previously [7]. The CYP2D6 poly-
morphisms refer to the CYP Allele Nomenclature Com-
mittee (http://www.cypalleles.ki.se) (eTable). Women were
classified as having an extensive, heterozygous extensive/
intermediate or poor CYP2D6 metabolism [7].
Mammogram collection and assessment of
mammographic density
Collection of mammograms for the parent study was
performed retrospectively. Using national registration
numbers [13] that are assigned to all subjects living in
Sweden, the current addresses from 1975 to 1995 were
obtained for all participants in the parent study through
a nationwide population registry. Mammograms were
then retrieved from radiology departments conducting
screening mammography for those addresses. Mammo-
grams were digitized by the Array 2905HD Laser Film
Digitizer, with density resolution set at 12-bit, spatial
resolution at 5.0 μm and optical density 0 to 4.7.
Mammographic breast density at baseline (≤1 year prior
to initiation of tamoxifen) and 6 to 36 months after treat-




Overlap with women with mammograms retrieved 570
Nonmissing date of initiation of tamoxifen therapy 562
Duration of treatment ≥6 months 530
Complete set of baseline and follow-up mammograms 309
Postmenopausal at baseline 308
Genotyped from blood 278
Baseline percent mammographic density (PMD) ≥10% 186method [14] and expressed as a percentage of the total
breast area (percent mammographic density, PMD). The
observed correlation between PMD measured by the
current gold standard, a computer-assisted semi-automatic
thresholding method named Cumulus, and the automated
thresholding method used here was (r = 0.88; 95% CI, 0.87
to 0.89) in an external test set [14]. For women with mul-
tiple mammograms available within the study period, the
image taken closest to the second year after treatment start
was selected for follow-up (median time from initiation =
1.96, interquartile range = 0.50).Radiotherapy 0.60
No 159 (64.4) 22 (71)
Yes 88 (35.6) 9 (29)
Tamoxifen (mg)
20 137 (55.5) 13 (41.9) 0.47
40 50 (20.2) 9 (29.0)
20 and 40 57 (23.1) 9 (29.0)
*Others 3 (1.2) 0 (0)
Description of selected characteristics in subjects with less than or greater than a
10% percent mammographic density (PMD) reduction, with P values for
association. Categorical variables (frequencies (%)) were assessed for association
using chi-squared tests, while continuous variables (means ± standard deviation
(SD)) were assessed using Kruskal-Wallis tests. *One woman was prescribed an
unknown dose of tamoxifen. Two women were prescribed tamoxifen citrate and
two were prescribed toremifene, a chlorinated derivative of tamoxifen.
HRT, hormone replacement therapy; BMI, body mass index; ER, estrogen receptor.
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Our primary endpoint was change in PMD between follow-
up and baseline. As change in PMD and absolute mammo-
graphic dense area were highly correlated (Spearman’s rho
correlation coefficient = 0.89) in our data, we limited our
association analysis CYP2D6 metabolizer status and mam-
mographic density to PMD change. To identify other covar-
iates (confounders) for PMD change, we explored the role
of baseline PMD, age at diagnosis (years), body mass index
(BMI) (kg/m2) at baseline, time difference between baseline
and follow-up mammograms (years), history of ever
hormone replacement therapy and estrogen receptor
(ER) (negative, positive or missing) status using chi-
squared and Kruskal-Wallis tests. As there might be
mammographic changes caused by other cancer treat-
ments, we also assessed chemotherapy [15] and ever
radiotherapy [16,17] as potential confounders. Variables
which were found to be significantly associated with
PMD change were retained in the final logistic regres-
sion model and adjusted for. Linear regression models
were initially applied to examine PMD change as a con-
tinuous variable. The Wald test was used to determine
the statistical significance of an overall linear trend for
the association between CYP2D6 metabolizer status,
treated as a semi-continuous variable, and binary PMD
change (P trend). For univariate analyses involving PMD
change (continuous variable), baseline and follow-up
PMD, the nonparametric Cuzick’s test for trend was alsoTable 3 Results of linear regression analyses
Univariate
n Beta SE Pwald Ptren
PMD change (continuous)*
EM 122 0.00 Reference 0.053
hetEM/IM 136 1.47 0.78 0.06
PM 20 1.89 1.51 0.21
Adjusted R2 0.01
Baseline PMD†
EM 122 0.00 Reference 0.389
hetEM/IM 136 −0.24 0.17 0.16
PM 20 0.00 0.33 1.00
Adjusted R2 0.001
Follow-up PMD†
EM 122 0.00 Reference 0.831
hetEM/IM 136 −0.07 0.15 0.64
PM 20 0.23 0.30 0.44
Adjusted R2 −0.00
Results of linear regression analyses treating the absolute difference between follow
continuous variable, and PMD at baseline and follow-up separately. PMD at baselin
mammographic density (PMD), age at baseline (years), and body mass index at bas
standard error; Pwald, P value from Wald tests; Ptrend, P value from Wald tests trea
Cuzick’s test for trend; EM, extensive metabolizer; hetEM/IM, heterozygous extensiveused (Pnptrend). The goodness-of-fit and proportion of
total variance explained by linear regression models
with more than one predictor variable were assessed
using adjusted R2 statistics. Odds ratios (ORs) and 95%
confidence intervals (CIs) (lower bound of a 95% confi-
dence interval (L95), upper bound of a 95% confidence
interval (U95)) were estimated by applying a logistic re-
gression model, using the group with 10% reduction as
a reference. Goodness-of-fit of logistic regression
models was tested using the Hosmer-Lemeshow test. A
P value of ≤0.05 was considered statistically significant.
All statistical tests were two-sided. Statistical analyses
were performed using R (version 2.15.1) [18].
The dataset consisted of 308 subjects who were post-
menopausal at baseline and who underwent treatment
for ≥6 months. Genetic variants in CYP2D6 assayed from
tumor-derived DNA are at risk of misclassification due to
loss of heterozygosity [19,20], hence we restricted our ana-
lysis to 278 patients with genotypes derived from blood.
Results and discussion
Table 2 shows that PMD change as a binary variable was
significantly associated with age (P = 0.05) and BMI (P =
0.02) at baseline, and strongly associated with baseline
PMD (P <0.001), results which are corroborated by pre-
vious findings [21,22]. Both age and BMI at baseline
were also found to be highly significantly associated with
baseline PMD (P <0.001).Adjusted
d Pnptrend Beta SE Pwald Ptrend












-up and baseline values in percent mammographic density (PMD) as a
e or follow-up was square-root transformed. *Adjusted for baseline percent
eline (kg/m2). †Adjusted for all of the above except for baseline PMD. SE,
ting genotypes (0, 1, 2) as a continuous variable; Pnptrend, P value from
/intermediate; PM, poor metabolizer; adjusted R2, adjusted R2 statistic.
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change as a continuous variable revealed a nonsignificant
trend of less PMD decline with reduced CYP2D6 func-
tionality (P = 0.11, Table 3). The variance of PMD change
as a quantitative trait explained by CYP2D6 metabolizer
status was modest (approximately 1.0%), although in keep-
ing with most genetic studies of traits assaying common
genetic variants of low penetrance [23]. CYP2D6 metabo-
lizer status was not associated with either baseline or
follow-up mammogram alone (Table 3), which agrees with
previous findings that PMD does not predict survival
when considered at single time points [5,24].
As the use of categorical cutoff points allows for an easy
application and interpretation, we a priori specified and
dichotomized the difference between PMD at follow-up
and baseline into ≤10% reduction and >10% reduction. A
PMD change of 10% has been reported to be the mini-
mum difference that could be reproducibly detected by
visual assessment [3,4]. Four examples of approximately
10% PMD reduction are shown in Figure 1.
When using this cutoff, our data is consistent with the
hypothesis that women with reduced CYP2D6 function
are less likely to experience a decline in PMD. PMD
change during tamoxifen therapy was found to beFigure 1 Examples of approximately 10% percent mammographic de
mammograms of the same breast.significantly associated with the degree of functionality
of CYP2D6 (Ptrend = 0.020, Table 4). Compared with
women who were extensive metabolizers of tamoxifen,
intermediate and poor metabolizers were 72% (95% CI:
0.10 to 0.79) and 71% (0.03 to 2.62) less likely to experi-
ence a >10% reduction, respectively. As it is difficult for
women with low baseline PMD to experience a >10%
PMD change, we repeated the analyses for a subgroup of
women with baseline PMD ≥10% (n = 186). The signifi-
cant association between CYP2D6 metabolizer status
and PMD change persisted (Ptrend = 0.021, Table 4).
Further adjustment of other potential confounders did
not change the estimates appreciably (data not shown).
Given the current discussion on genotype-driven tam-
oxifen dosing [25,26], we further adjusted for drug dos-
age to account for effective therapeutic metabolite
ranges of different CYP2D6 metabolizer status, but did
not observe an appreciable change in the results (data
not shown). The boxplot in Figure 2 shows graphically
that PMD reduction was weaker with genetic CYP2D6
deficiency. It has recently been shown that mammo-
graphic density at time of breast cancer diagnosis did
not influence breast cancer prognosis [5,24], but while
mammographic density did not have a bearing onnsity reduction from baseline (left) to follow-up (right)
Table 4 Results of tests of association between CYP2D6 metabolizer variants and change in percent mammographic
density
PMD reduction Univariate Adjusted
≤10% >10% OR L95 U95 Ptrend OR L95 U95 Ptrend
+ Genotyped from whole blood
EM 101 21 1.00 Reference 0.009 1.00 Reference 0.020
hetEM/IM 127 9 0.34 0.15 0.78 0.28 0.10 0.79
PM 19 1 0.25 0.03 2.00 0.29 0.03 2.62
n = 278
GOF 0.928
+ Genotyped from whole blood
+ Baseline PMD ≥10%
EM 63 21 1.00 Reference 0.010 1.00 Reference 0.021
hetEM/IM 79 9 0.34 0.15 0.80 0.29 0.11 0.81
PM 13 1 0.23 0.03 1.87 0.29 0.03 2.57
n = 186
GOF 0.609
Results of tests of association between CYP2D6 metabolizer variants and change in percent mammographic density (PMD) in subjects treated with tamoxifen for
at least six months. Mammograms were taken ≤1 year prior to initiation of tamoxifen, up to three years after treatment. The mammogram taken closest to the
second year after tamoxifen treatment was selected for follow-up. Odds ratios (ODs) and 95% confidence intervals (CIs) (lower bound of a 95% confidence interval
(L95), upper bound of a 95% confidence interval (U95)) were estimated by applying a logistic regression model, using the group with 10% reduction as a
reference. Analyses were adjusted for baseline PMD, age at diagnosis (years), and body mass index (kg/m2) at baseline. The Wald test was used to determine the
statistical significance of an overall linear trend for the association between CYP2D6 metabolizer status, treated as a semi-continuous variable, and PMD change
(Ptrend). All statistical tests were two-sided. Statistical analyses were performed using R (version 2.15.1) [18]. EM, extensive metabolizer; hetEM/IM, heterozygous

























Figure 2 Boxplot of percent mammographic density (PMD) change by CYP2D6 metabolizer status. Boxplot of percent mammographic
density (PMD) change by CYP2D6 metabolizer status for subjects genotyped from whole blood and with baseline PMD ≥10% (n = 186). The
maximum length of each whisker is 1.5 times the interquartile range. EM, extensive metabolizer; hetEM/IM, heterozygous extensive/intermediate;
PM, poor metabolizer.
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we reported that a pronounced decrease in mammo-
graphic density between baseline and follow-up mam-
mograms following tamoxifen treatment was found to
significantly reduced the risk of dying from breast cancer
in a previous study [5]. An independent study in an Asian
population also showed that mammographic density
change during short-term use of adjuvant endocrine ther-
apy was also found to be a significant predictor of long-
term recurrence in women with ER-positive breast cancer
[3]. It is conceivable that the association between PMD
change and breast cancer survival in patients treated with
tamoxifen could be explained by differences in compliance
or in this case, an inherited response to treatment (for ex-
ample due to genetic variation in the CYP2D6 gene).
Nonetheless, two large trials have previously reported
a null association between CYP2D6 genotype and breast
cancer outcome [27,28], which appears to contradict our
findings. The validity of the two studies, however, has
been questioned due to the quality of genotyping on the
basis of massive departures from Hardy-Weinberg equi-
librium and the use of tumor tissue [29]. In this study,
we have addressed the concerns and restricted our ana-
lysis to germline DNA extracted from blood. The indi-
vidual genotype counts of CYP2D6 metabolizer status
were also presented in the results.
To the best of our knowledge, this is the first time that
CYP2D6 has been shown to influence PMD change. A
major strength is the comprehensive assembly of various
datasets, which helped to give rise to a new mechanistic
insight on a putative relationship between active metab-
olites, as predicted by CY2D6 metabolizer status, and
local morphological changes. Using a fully automatic
thresholding method to measure PMD on serial mam-
mograms adds to the strength of our study as intra- and
interreader variability was substantially reduced. The
method produces one reproducible reading per mammo-
gram; unlike other user-dependent methods, in which
readings can vary when a mammogram is reread by the
same user, or read by another user. However, due to a
limitation in size of the study, validation of our findings
in an independent dataset is of critical importance. A
lack of adequate data prevents the ruling out of the im-
pact of CYP2D6 inhibitors on the results.
Conclusions
In conclusion, our exploratory study has yielded prelim-
inary evidence to show that there is a significant associ-
ation between CYP2D6 metabolizer status and PMD
change, suggesting that the capacity for PMD change
may be inherited. Although the sample size is limited,
our finding may still be clinically important and warrant
further consideration. The question of whether CYP2D6
could be used as a risk or prognostic marker formammographic density changes in response to tamoxi-
fen treatment will require larger prospective studies.
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